Astro-Med, Inc. (Astronova) 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for Astro-Med, Inc. (referred to as Astronova in the request metadata, but Astro-Med in the filing) for the quarterly period ended August 1, 2009. The company is a manufacturer of specialty high-tech printing systems, electronic medical instrumentation, and test and measurement instruments. It operates through three segments: Test & Measurement (T&M), QuickLabel Systems, and Grass Technologies (GT). The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Aug 1, 2009 | Six Months Ended Aug 1, 2009 |
|---|---|---|
| Net Sales | $16.42 million | $31.09 million |
| Gross Profit | $6.95 million | $12.76 million |
| Gross Margin | 42.3% | 41.0% |
| Operating Income | $0.89 million | $0.43 million |
| Net Income | $0.59 million | $0.35 million |
| Diluted EPS | $0.08 | $0.05 |
| Cash and Equivalents | $14.59 million (Balance Sheet) | $14.59 million (Balance Sheet) |
| Operating Cash Flow | N/A | $0.69 million |
| Total Debt | $0 (No long-term debt reported) | $0 |
| Working Capital | $40.99 million | $40.99 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 17.0% in the quarter and 19.2% for the six-month period compared to the prior year, driven by the global recession and reduced capital equipment purchases.
- Profitability Compression: Operating income fell 54.1% for the quarter and 86.8% for the six-month period. Net income dropped 49.3% for the quarter and 82.7% for the six-month period.
- Segment Performance:
- QuickLabel: Sales declined 23.4% (quarter) and 23.3% (six months), the largest drop among segments.
- Test & Measurement: Sales declined 13.7% (quarter) and 10.7% (six months), impacted by aerospace manufacturing delays.
- Grass Technologies: Sales declined 5.7% (quarter) and 18.0% (six months), though operating profit increased 31.9% in the quarter due to expense reductions.
- Cost Reductions: Operating expenses decreased 10.2% for the quarter and 9.6% for the six months due to wage freezes, layoffs, and deferred capital expenditures.
- Liquidity: Cash and cash equivalents increased by $3.61 million during the six-month period, primarily due to proceeds from the sale of securities available for sale.
Outlook, Risks, and Management Commentary
- Management Commentary: Management attributes the sales decline to the worldwide recession, noting customers are deferring capital purchases and limiting consumable inventory. The company has implemented a cost-reduction initiative but is maintaining Research and Development (R&D) spending to ensure future growth.
- Guidance: The filing does not provide specific numerical guidance for future periods. Management states that interim results are not necessarily indicative of full-year results.
- Risks and Contingencies:
- Economic Conditions: Continued global recession and declining demand in defense, aerospace, and industrial markets.
- Foreign Exchange: Unfavorable foreign exchange rates negatively impacted international sales by $446,000 in the quarter and $1.19 million for the six months.
- Investment Portfolio: The company holds $894,215 in auction rate securities (Level 3 assets) which are not currently trading. While management believes the unrealized loss is temporary, these assets lack liquidity.
- Customer Concentration: Risks related to major suppliers or customers facing financial difficulties.
- Unusual Items: No unusual items were reported. The company returned to profitability in the second quarter after a loss in the first quarter of the fiscal year.
Investor Verification Checklist
- Verify the liquidity status and potential valuation of the $894,215 in auction rate securities, which are classified as Level 3 assets and currently lack a readily determinable market value.
- Monitor the backlog, which decreased 13.5% to $5.54 million, as an indicator of future revenue visibility.
- Assess the sustainability of the cost-reduction initiatives (layoffs, wage freezes) and their impact on long-term operational capacity and R&D output.
- Review the accounts receivable collection cycle, which increased from 50 days to 54 days, indicating potential collection pressures.
- Confirm the impact of foreign exchange rates on future international sales, given the significant negative impact in the current period.